SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Pacira BioSciences, Inc. – ‘10-Q’ for 6/30/15 – ‘EX-10.1’

On:  Thursday, 7/30/15, at 4:32pm ET   ·   For:  6/30/15   ·   Accession #:  1396814-15-9   ·   File #:  1-35060

Previous ‘10-Q’:  ‘10-Q’ on 4/30/15 for 3/31/15   ·   Next:  ‘10-Q’ on 10/27/15 for 9/30/15   ·   Latest:  ‘10-Q’ on 11/2/23 for 9/30/23   ·   4 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 7/30/15  Pacira BioSciences, Inc.          10-Q        6/30/15   72:5.7M

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        10-Q 6-30-15                                        HTML    457K 
 2: EX-10.1     Material Contract -- exhibit101                     HTML     46K 
 3: EX-10.2     Material Contract -- exhibit102                     HTML     28K 
 4: EX-10.3     Material Contract -- exhibit103                     HTML     28K 
 5: EX-10.4     Material Contract -- exhibit104                     HTML     28K 
 6: EX-10.5     Material Contract -- exhibit105                     HTML     28K 
 7: EX-10.6     Material Contract -- exhibit106                     HTML     46K 
 8: EX-10.7     Material Contract -- exhibit107                     HTML     42K 
 9: EX-31.1     Certification -- §302 - SOA'02                      HTML     27K 
10: EX-31.2     Certification -- §302 - SOA'02                      HTML     27K 
11: EX-32.1     Certification -- §906 - SOA'02                      HTML     20K 
12: EX-32.2     Certification -- §906 - SOA'02                      HTML     20K 
49: R1          Document and Entity Information                     HTML     41K 
39: R2          Consolidated Balance Sheets                         HTML    108K 
47: R3          Consolidated Balance Sheets (Parenthetical)         HTML     44K 
51: R4          Consolidated Statements of Operations               HTML     85K 
66: R5          Consolidated Statements of Comprehensive Loss       HTML     36K 
41: R6          Consolidated Statement of Stockholders' Equity      HTML     64K 
46: R7          Consolidated Statements of Cash Flows               HTML    115K 
36: R8          Description of Business                             HTML     26K 
29: R9          Summary of Significant Accounting Policies          HTML     44K 
67: R10         Inventories                                         HTML     31K 
53: R11         Fixed Assets                                        HTML     40K 
52: R12         Goodwill and Intangible Assets                      HTML     77K 
57: R13         Debt                                                HTML     71K 
58: R14         Financial Instruments                               HTML     99K 
56: R15         Stock Plans                                         HTML     83K 
59: R16         Stockholders' Equity                                HTML     40K 
48: R17         Net Income (Loss) Per Share                         HTML     74K 
50: R18         Taxes                                               HTML     42K 
55: R19         Commitments and Contingencies                       HTML     39K 
72: R20         Summary of Significant Accounting Policies          HTML     47K 
                (Policies)                                                       
62: R21         Summary of Significant Accounting Policies          HTML     36K 
                (Tables)                                                         
43: R22         Inventories (Tables)                                HTML     30K 
54: R23         Fixed Assets (Tables)                               HTML     35K 
45: R24         Goodwill and Intangible Assets (Tables)             HTML     70K 
24: R25         Debt (Tables)                                       HTML     58K 
63: R26         Financial Instruments (Tables)                      HTML     91K 
68: R27         Stock Plans (Tables)                                HTML     84K 
32: R28         Stockholders' Equity (Tables)                       HTML     33K 
31: R29         Net Income (Loss) Per Share (Tables)                HTML     73K 
34: R30         TAXES Taxes (Tables)                                HTML     37K 
35: R31         Commitments and Contingencies (Tables)              HTML     29K 
37: R32         Summary of Significant Accounting Policies          HTML     33K 
                (Details)                                                        
23: R33         Inventories (Details)                               HTML     31K 
60: R34         Fixed Assets (Details)                              HTML     47K 
42: R35         Goodwill and Intangible Assets (Details)            HTML     50K 
44: R36         Goodwill and Intangible Assets (Details 2)          HTML     31K 
27: R37         Goodwill and Intangible Assets (Details 3)          HTML     53K 
70: R38         Debt (Details)                                      HTML     50K 
19: R39         Debt (Details 2)                                    HTML     85K 
38: R40         Financial Instruments (Details)                     HTML     44K 
65: R41         Financial Instruments (Details 2)                   HTML     52K 
26: R42         Financial Instruments (Details 3)                   HTML     36K 
30: R43         Stock Plans (Details)                               HTML     46K 
33: R44         Stock Plans (Details 2)                             HTML     43K 
40: R45         Stock Plans (Details 3)                             HTML     45K 
22: R46         Stockholders' Equity (Details)                      HTML     32K 
28: R47         Stockholders' Equity Follow-On Public Offering      HTML     20K 
                (Details)                                                        
20: R48         Net Income (Loss) Per Share (Details)               HTML     57K 
64: R49         Net Income (Loss) Per Share (Details 2)             HTML     32K 
25: R50         Taxes (Details)                                     HTML     31K 
61: R51         Commitments and Contingencies (Details)             HTML     38K 
69: XML         IDEA XML File -- Filing Summary                      XML    109K 
21: EXCEL       IDEA Workbook of Financial Reports                  XLSX     59K 
13: EX-101.INS  XBRL Instance -- pcrx-20150630                       XML   1.53M 
15: EX-101.CAL  XBRL Calculations -- pcrx-20150630_cal               XML    183K 
16: EX-101.DEF  XBRL Definitions -- pcrx-20150630_def                XML    391K 
17: EX-101.LAB  XBRL Labels -- pcrx-20150630_lab                     XML   1.20M 
18: EX-101.PRE  XBRL Presentations -- pcrx-20150630_pre              XML    660K 
14: EX-101.SCH  XBRL Schema -- pcrx-20150630                         XSD    125K 
71: ZIP         XBRL Zipped Folder -- 0001396814-15-000009-xbrl      Zip    157K 


‘EX-10.1’   —   Material Contract — exhibit101


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Exhibit 10.1  


Exhibit 10.1

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR THE REDACTED PORTIONS OF THIS EXHIBIT. THE REDACTIONS ARE INDICATED WITH “[**]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION.

THIRD AMENDMENT TO
COMMERCIAL OUTSOURCING SERVICES AGREEMENT

This Third Amendment to the Commercial Outsourcing Services Agreement (this “Amendment”) is between Pacira Pharmaceuticals, Inc. (the “Company”) and Integrated Commercialization Solutions, Inc. (“ICS”). This Amendment is effective as of December 1, 2014 (the “Amendment Effective Date”).

RECITALS

A.
The Company and ICS are parties to a Commercial Outsourcing Services Agreement dated August 25, 2011, as amended by the First Amendment dated August 1, 2013 and the Second Amendment dated August 25, 2014 (as amended, the “Agreement”);

B.
Pursuant to the Agreement, among other things, the Company engaged ICS to perform commercialization services for certain pharmaceutical products; and

C.
The parties now wish to amend the Agreement in certain respects.

AMENDMENT

NOW THEREFORE, the parties agree as follows:

1.
Defined Terms. Capitalized terms in this Amendment that are not defined in this Amendment have the meanings given to them in the Agreement. If there is any conflict between the Agreement and any provision of this Amendment, this Amendment will control.

2.
Schedule B.     The parties agree that Schedule B to the Agreement is hereby deleted in its entirety and replaced with the attached Revised Schedule B. The Revised Schedule B includes an agreed upon reduction of the Company’s freight mark-up fee provided that the Company continues to use ICS’s UPS account for the Term of this Agreement. In the event that the Company decides to use its own UPS account, ICS reserves the right to revise the fees in the Revised Schedule B.   

3.
No Other Changes. Except as otherwise provided in this Amendment, the terms and conditions of the Agreement will continue in full force.

IN WITNESS WHEREOF, the parties have executed this Amendment as of the Amendment Effective Date.

Integrated Commercialization Solutions, Inc.         Pacira Pharmaceuticals, Inc.

By: /s/ Peter Belden                    By: /s/ Anthony Molloy        

Name: Peter Belden                    Name: Anthony Molloy

Title: President                        Title: Associate General Counsel
                            
Date: April 29, 2015



[**] - Indicates certain information has been redacted and filed separately with the U.S. Securities and Exchange Commission. Confidential treatment has been requested with respect to the redacted portions.




REVISED SCHEDULE B
ICS 3PL SCHEDULE OF FEES

Fee
Amount
Description
Monthly Management Fee
Customer Service
Warehouse & Distribution
Returns Management
Finance
Information Technology & Reporting
Chargeback Management
Sample Management
Marketing Material Management




Sunday Shipments
$[**]













$[**]
[**]













[**]
Customer Service Fees
EDI Order Processing Fees
















Manual Order Processing Fees
$[**]

$[**]

$[**]

$[**]

$[**]








$[**]
        [**]
Customer Setup Fee
$[**]
[**]
Account Maintenance/ License Updates
$[**]
[**]
Drop Shipment Surcharge
$[**]
[**]
Allocation Fee
$[**]
[**]
Rush Order
$[**]
[**]
Emergency Order
$[**]
[**]
International Order
$[**]
[**]

[**] - Indicates certain information has been redacted and filed separately with the U.S. Securities and Exchange Commission. Confidential treatment has been requested with respect to the redacted portions.




Warehouse & Distribution Fees
Product Storage - Refrigerated
$[**]


$[**]

$[**]
[**]
Product Storage - Ambient
$[**]
[**]
Trade Order Processing Fees
$[**]

$[**]

$[**]

$[**]

$[**]

+

$[**]

$[**]

$[**]

$[**]

$[**]

[**]
Receiving Fee
$[**]
[**]
Shipping Fee
$[**]
[**]
Bulk Shipments
$[**]
[**]
Packing Supplies
$[**]
[**]
Freight
$[**]
[**]
Finance
Invoice Processing
$[**]
[**]
Credit Verification Reports - Dun & Bradstreet
$[**]
[**]
Credit Verifications Reports - Experian
$[**]
[**]
Returns Management
RGA Initiation
$[**]
+
$[**]
[**]
Return Processing
$[**]
[**]
Partial Returns Processing
$[**]
[**]
Returns Storage
$[**]
[**]
Contract and Chargeback Management
Chargeback Processing - Manual
$[**]
[**]
Chargeback Processing - Electronic
$[**]
[**]
Membership Additions
$[**]
[**]

[**] - Indicates certain information has been redacted and filed separately with the U.S. Securities and Exchange Commission. Confidential treatment has been requested with respect to the redacted portions.




Contract Setup
$[**]
[**]
Contract Updates
$[**]
[**]
Information Technology and Reporting
852/867: ABC, CAH, MCK
$[**]
[**]
Custom Reports
$[**]
[**]
Custom Development Services
$[**]
[**]
Additional Fees
Product Destruction
$[**]
[**]
Telecom
$[**]
[**]
FedEx/UPS/Postage Expenses
$[**]
[**]
Pre-Approved Assessorial Labor Charge - Warehouse
$[**]
[**]
Pre-Approved Assessorial Labor Charge - Office Staff
$[**]
[**]
Pre-Approved Assessorial Labor Charge - QC, Management
$[**]
[**]
ICS Travel
$[**]
[**]



[**] - Indicates certain information has been redacted and filed separately with the U.S. Securities and Exchange Commission. Confidential treatment has been requested with respect to the redacted portions.


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
Filed on:7/30/158-K
For Period end:6/30/15
4/29/15
12/1/14
8/25/144,  8-K
8/1/13
8/25/11
 List all Filings 


4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/29/24  Pacira BioSciences, Inc.          10-K       12/31/23  123:17M
 2/28/23  Pacira BioSciences, Inc.          10-K       12/31/22  118:16M
 2/28/22  Pacira BioSciences, Inc.          10-K       12/31/21  128:17M
 3/01/21  Pacira BioSciences, Inc.          10-K       12/31/20  113:13M
Top
Filing Submission 0001396814-15-000009   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., May 4, 1:48:35.1am ET